Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 2/20 | 0.44 |
| ▸ | CD22 | P20273 | 14/20 | 0.39 |
| ▸ | MAG | P20916 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12730475 | 1.00 | NANP (0.44) | NANPCD22MAG | |
| SCHEMBL14454528 | 1.00 | NANP (0.44) | NANPCD22MAG | |
| SCHEMBL15677307 | 0.93 | NANP (0.51) | NANPCD22MAG | |
| SCHEMBL12341462 | 0.92 | NANP (0.47) | NANPCD22MAG | |
| SCHEMBL13477004 | 0.91 | NANP (0.40) | NANPCD22 | |
| SCHEMBL14175641 | 0.91 | NANP (0.40) | NANPCD22 | |
| SCHEMBL12341459 | 0.90 | NANP (0.39) | NANPCD22MAG | |
| SCHEMBL14366095 | 0.90 | NANP (0.44) | NANPCD22MAG | |
| SCHEMBL12991357 | 0.90 | NANP (0.44) | NANPCD22MAG | |
| SCHEMBL14752226 | 0.89 | NANP (0.43) | NANPCD22MAG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187546-B2 | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants | NOVO NORDISK A/S (DK) | 2015-11-17 | — | — | US | disclosed |
| US-9029331-B2 | Glycopegylated granulocyte colony stimulating factor | NOVO NORDISK A/S (DK) | 2015-05-12 | — | — | US | disclosed |
| US-8911967-B2 | One pot desialylation and glycopegylation of therapeutic peptides | NOVO NORDISK A/S (DK) | 2014-12-16 | — | — | US | disclosed |
| US-8632770-B2 | Glycopegylated factor IX | NOVO NORDISK A/S (DK) | 2014-01-21 | — | — | US | disclosed |
| US-8404809-B2 | Glycopegylated factor IX | NOVO NORDISK A/S (DK) | 2013-03-26 | — | — | US | disclosed |
| US-8268967-B2 | Glycopegylated interferon α | NOVO NORDISK A/S (DK) | 2012-09-18 | — | — | US | disclosed |
| US-7956032-B2 | Glycopegylated granulocyte colony stimulating factor | NOVO NORDISK A/S (DK) | 2011-06-07 | — | — | US | disclosed |
| US-20110003744-A1 | Glycopegylated Erythropoietin Formulations | NOVO NORDISK A/S (DK) | 2011-01-06 | — | — | US | disclosed |
| US-20100330645-A1 | ONE POT DESIALYLATION AND GLYCOPEGYLATION OF THERAPEUTIC PEPTIDES | NOVO NORDISK A/S (DK) | 2010-12-30 | — | — | US | disclosed |
| US-20100330060-A1 | GLYCOPEGYLATED FACTOR IX | NOVO NORDISK A/S (DK) | 2010-12-30 | — | — | US | disclosed |
| US-20090081188-A1 | GLYCOPEGYLATED FACTOR IX | NEOSE TECHNOLOGIES, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20090028822-A1 | Glycopegylated Interferon Alpha | NEOSE TECHNOLOGIES, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20080305992-A1 | Glycopegylated erythropoietin | NEOSE TECHNOLOGIES, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080300173-A1 | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] | NOVO NORDISK A/S (DK) | 2008-12-04 | — | — | US | disclosed |
| US-20080255026-A1 | Glycopegylated Factor Ix | GLYCOPEGYLATED FACTOR 1X | 2008-10-16 | — | — | US | disclosed |
| US-20080176790-A1 | Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf) | 89BIO, INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080146782-A1 | GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES | NEOSE TECHNOLOGIES, INC. (US) | 2008-06-19 | — | — | US | disclosed |
| US-20070154992-A1 | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants | NEOSE TECHNOLOGIES, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070105755-A1 | One pot desialylation and glycopegylation of therapeutic peptides | NEOSE TECHNOLOGIES, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070014759-A1 | Glycopegylated granulocyte colony stimulating factor | NEOSE TECHNOLOGIES, INC. (US) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176790-A1 | Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf) | FGF2, FGF1, FGFR1 | NANP 163/4885CD22 392/4885MAG 711/4885 |
| US-20090028822-A1 | Glycopegylated Interferon Alpha | IFNG, IFNAR1, OGT | NANP 366/4885CD22 383/4885MAG 924/4885 |
| US-20100330060-A1 | GLYCOPEGYLATED FACTOR IX | F9, F13A1, F13B | NANP 160/4885CD22 382/4885MAG 212/4885 |
| US-20080146782-A1 | GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES | UGCG, B3GAT3, UGGT1 | NANP 306/4885CD22 367/4885MAG 119/4885 |
| US-20090081188-A1 | GLYCOPEGYLATED FACTOR IX | F9, F13A1, F13B | NANP 160/4885CD22 382/4885MAG 212/4885 |
| US-20110003744-A1 | Glycopegylated Erythropoietin Formulations | EPOR, UGGT1, GNE | NANP 838/4885CD22 375/4885MAG 298/4885 |
| US-20080255026-A1 | Glycopegylated Factor Ix | F9, F13A1, F13B | NANP 156/4885CD22 390/4885MAG 194/4885 |
| US-20070105755-A1 | One pot desialylation and glycopegylation of therapeutic peptides | UGGT1, PTMS, GALNT1 | NANP 832/4885CD22 210/4885MAG 802/4885 |
| US-20070014759-A1 | Glycopegylated granulocyte colony stimulating factor | CSF3R, GMFG, GALNT1 | NANP 701/4885CD22 203/4885MAG 228/4885 |
| US-20080300173-A1 | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] | GLP1R, GIPR, IAPP | NANP 896/4885CD22 433/4885MAG 736/4885 |
| US-20080305992-A1 | Glycopegylated erythropoietin | EPOR, UGGT1, GNE | NANP 864/4885CD22 290/4885MAG 265/4885 |
| US-20070154992-A1 | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants | GHITM, PTMS, GHRHR | NANP 386/4885CD22 2233/4885MAG 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.